University Medical Center Hamburg-Eppendorf, Germany



Similar documents
Department of Medical Biochemistry, Oslo University Hospital, Rikshospitalet, Oslo Norway, Norway

German Mesothelioma Register

Rehabilitation and MS-Centre Overpelt, Belgium

Riga Centre of Psychiatry and Addiction Medicine, Latvia

German Social Accident Insurance, DGUV, Germany

Entidade Reguladora da Saúde ERS (Portuguese Health Regulatory Authority), Portugal

UEMS. Section/ European Board and College of Obstetrics and Gynaecology, Belgium

Groupe MGEN - Mutuelle Générale de l'education Nationale, France

Ministère des Affaires Sociales et de la Santé, France

Board of Member States ERN implementation strategies

ACRONIM : InNerMeD-I-Network. STARTING DATE: DURATION (in months): 30. PRIORITY AREA: Actions under the second objective 'Promote health'

COMMISSION OF THE EUROPEAN COMMUNITIES

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

Policy proposals to improve access to multiple sclerosis treatments in Europe

Third EU Health Programme

CLINICAL RESEARCH NETWORK

Vårdförbundet s views on healthcare management

The European regulatory system for medicines and the European Medicines Agency

2016 MEDICAL REHABILITATION PROGRAM DESCRIPTIONS

Sample Position Description Nurse Practitioner GS-12. Introduction

EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases

Document: Work of the High Level Group on health services and medical care during 2005

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C Report of Foreign Private Issuer

CHILDREN S NEUROSCIENCE CENTER

ENS4Care Questionnaire

THE LINCOLN INSTITUTE OF HEALTH

SSNAP s Acute Organisational Audit Report 2012: Performance Summary for South London

EPF Position Statement on the European Commission s proposal for a Regulation on In Vitro Medical Devices

MANAGEMENT OF DATA, INFORMATION AND KNOWLEDGE IN MEDICINE AND HEALTH SERVICES in SR

Dr Rainald von Gizycki. Board member European Patients Forum (EPF)

Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020

Pediatric Research Networks A Plan for a Collaboration in Europe. Daniela Gunz Head Clinical Trial Operations Switzerland June 9, 2011

VISION STATEMENT. Guiding principles:

When it comes to health

What is Palliative Care

Research Agenda and Opportunities for Co-Funding

Overcoming cancer with research Vienna 15 th -17 th May, Session 3: Established therapeutic compounds

ECRIN General Presentation

EURORDIS Position Paper on Specialised Services for People Living with Rare Diseases

Engineering for the new pharma reality

Written Contribution of the National Association of Statutory Health Insurance Funds of

2013/14 Choice Framework

Estate Planning and Patients' Rights in Cross-Border Healthcare

Introduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)

Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements

Clinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission

Call-A-Nurse Location

Clinical support roles in pediatric and neonatal settings across Europe

Children and Families Commission (office) (Cell)

International Services

Nursing Knowledge for Your Benefit

Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services

Kevin B. Weiss, MD, MPH Senior Vice President for Institutional Accreditation

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine

Physical Therapy. Prestigious Adventurous Curious Studious Ambitious Ingenious

No. prev. doc.: 8770/08 SAN 64 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008

15350 Sherman Way, Suite 350 Van Nuys, CA Phone Fax April 17, 2015.

Employment, Social policy, Health and Consumer affairs Council meeting Brussels, 1 December 2014

Program Respiratory Therapy. Department Analytical and Diagnostic Sciences. College Allied Health Sciences. Year 2014

Response of the German Medical Association

A cross-platform model for secure Electronic Health Record communication

Accreditation of health informatics programs: How to accomplish? A.Hasman VP Special Affairs IMIA

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

SHAPING THE FUTURE OF HEALTH CARE

Opportunities for African Participation in H2020. Research and Innovation Work Programme

Breast. Patient information. cancer clinical pathway

HACETTEPE UNIVERSITY

Evolutionary different.

Choosing the Right Healthcare Providers. general information

A Career in Pediatric Hematology-Oncology? Think About It...

Università Vita-Salute San Raffaele. Prof. Lorenzo Dagna Delegate for International Relations Milan, October 3 rd 2011

Clients.

A competency framework for all prescribers updated draft for consultation

BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH

SUNY UPSTATE MEDICAL UNIVERSITY

Faculty of Nursing. Master s Project Manual. For Faculty Supervisors and Students

Child Abuse Pediatrics Fellowship Program. Child Protection Program Indiana University School of Medicine Riley Hospital for Children

Liver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to

FP7 - Research Potential 2011 call for proposals. Anna Rémond DG RTD/B4 European Commission

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

Promotion of a sustainable health workforce

IFMSA Policy Statement Global Policy on Medical Education

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire

Florida Hospital and UCF Health Open a Gateway to Better Health in Lake Nona

What You Need to Know About Lung Cancer Immunotherapy

East LCC COMPANY PRESENTATION

The importance of international. Collaborations in rare diseases

Stakeholder s Report SW 75 th Ave Miami, Florida

Swiss Package for German cross-border commuters. Feel at home with Swiss quality insurance cover.

The Cell Therapy Catapult

Program Specification for Master Degree in: Child & Adolescent Psychiatry

Sec PARTICIPATION AND REIMBURSEMENT OF TELEMEDICINE MEDICAL SERVICE PROVIDERS UNDER MEDICAID. (a) The commission by rule shall develop and

Master in Health Psychology. Master in Health Psychology

Blood Biobanking Chances and Risks. The Bavarian Red Cross Blood Donor Biobank

EHR4CR ENABLING PROACTIVE RESEARCH

Visions for the hospital service in Region Zealand We create the hospital-service of the future through coherence and development

WATSON FARLEY & WILLIAMS: KEY FACTS

ECRIN (European Clinical Research Infrastructures Network)

Transcription:

University Medical Center Hamburg-Eppendorf, Germany 1. Respondent Profile 1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation: Academic/public health and healthcare specialised institution/organisation (e.g. Institutes and University Departments of Public Health, Quality, Healthcare, Clinical Excellence) Please indicate level: National level organisation Please indicate for what the administration is responsible: 1.1.1. Other (please specify): Highest Level of Healthcare 1.2 Please indicate the name of your organisation or centre: University Medical Center Hamburg-Eppendorf 1.3 Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in Europe: DE 1.4 Please indicate the number of EU Member States and EEA countries (Norway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is represented: 2 1. If need be, can we contact you by e-mail to obtain further information on your submission? 1..1 Please provide an e-mail address where we can contact you: zeitz@uke.de

1.6 Please provide us with a contact person (incl jobtitle and daytime phone number): 1.7 Please provide additional contact details if needed: Professor Dr.med. Martin Zeitz Medical Director, CEO University Medical Center Hamburg-Eppendorf Martinistr.2, 20246 Hamburg Germany, Building Ost 3 Tel: +49 (0)407410 000 2. Involvement of your organisation in the matter of centres of excellence/reference (COE) and healthcare networks in highly specialised healthcare (HSHC). 2.1 How would you describe your organisation's knowledge of CoE and HSHC? Very high 2.1.1 Space for further comments: Highly specialized healthcare, centers of excellence, eg, stroke, cancer, autoimmune liver and metabolic disorders, rare diseases. Multiprofessional training site for students, MD, nurses, therapists 2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies) Highly specialised healthcare provision Costs and economic evaluation Ethical analysis Management and organisational aspects of highly specialized healthcare Social aspects Professional performance, clinical practice, quality and safety of specialized healthcare Assessment/evaluation/certification of clinical practice and healthcare providers Information system, coding Engineering/e-health

2.2.1. Space for further comments: HIMSS level-7 certified electronic clinical info. system (Soarian) funded by German Research Council. International trials, eg, WAKE-UP stroke trial (EU FP7), EU-project DEM Child (ceroidlipofusc.) 2.3 Is highly specialised healthcare a priority in your organisation's strategies and work plans? Very high 2.3.1 Space for further comments: Development and implementation of individualized therapies; bringing forward specialized personalized medicine, eg, individually adapted immunomodulation in autoimmune diseases or tumor therapy 2.4. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work? Medical/Surgical speciality Please specify: 2.. Has your organisation/centre been directly involved in the design or assessment of professional standards and criteria related with highly specialised healthcare? High-tech diagnostics/interventional services Frequently 2..1 Please describe your role in such actions/projects: 2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly specialised healthcare?

2.7. Do you have concrete examples based on your own organisation's experience or could you provide us with references or links to documents related with professional criteria and standards in highly specialised healthcare/coe or HSHC (e.g. quality criteria, guidelines, consensus documents)? 2.7.1 Space for further comments: eg, German Diagnosis and Treatment Guidelines in Neurology, European Association for the Study of the Liver (EASL) Clinical Practice Guidelines, National guidelines for different Diseases 2.13. What is the scope of the network? 2.14. Which kind of network? 2.14.1 Space for further comments: 2.1. Would you be interested in applying to the process to be considered Centre of Excellence of the future European Reference Network? (1 = not interested at all, = very interested) 2.1.1 Space for further comments: 3. Proposed criteria for ERN (scope, general and specific criteria) 3.1 Criteria related with diseases or conditions in order to be considered under the scope of the ERN 3.1.1. Need of highly specialised healthcare 3.1.1.1. Complexity of the diagnosis and treatment 3.1.1.2. High cost of treatment and resources 4 3.1.1.3. Need of advanced/highly specialised medical equipment or infrastructures

3.1.2. Need of particular concentration of expertise and resources 3.1.2.1. Rare expertise/need of concentration of cases 3.1.2.2. Low prevalence/incidence/number of cases 4 3.1.2.3. Evaluated experiences of Member States 3 3.1.3. Based on high-quality, accessible and cost-effective healthcare 3.1.3.1. Evidence of the safety and favourable risk-benefit analysis 4 3.1.3.2. Feasibility and evidence of the value and potential positive outcome (clinical) 3.1.4. Do you recommend any additional criteria or option that would effectively address the issue? 3.1.4.1 Explain your proposal in free text: 3.1.. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria? Focus is transitional medicine as several complex diseases requiring highly specialized healthcare impose interdisciplinary challenges to both pediatric and adult medicine specialties 3.1..1 Explain your proposal in free text: Advancing novel diagnostics/treatment of, eg, autoimmune liver diseases, pediatric lysosomal and metabolic diseases, complex neurovascular and neuroimmunological disorders, neurofibromatosis 3.2. General criteria of the centres wishing to join a European Reference Network

3.2.1. Organisation and management 3.2.2. Patients empowerment and centered care 3.2.3. Patient care, clinical tools and health technology assessment 4 3.2.4. Quality, patient safety and evaluation framework policies 4 3.2.. Business continuity, contingency planning and response capacity 4 3.2.6. Information systems, technology and e-health tools and applications 3.2.7. Overall framework and capacity for research and training 4 3.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in the ERN 3.2.9. Do you recommend any additional option that would effectively address the issue? 3.2.9.1. Space for further comments: Structured follow-up care programs für HSHC patients warranting quality management and evaluation of clinical pathways, transcultural patient care and foreign language competence for cross-border care 3.3. Specific criteria regarding the areas of expertise 3.3.1. Competence, experience and good outcomes and care 3.3.2. Specific resources and organisation:

3.3.2.1. Human resources 3.3.2.2. Team/centre organisation 3.3.2.3. Structural conditions 4 3.3.2.4. Specific equipment 3.3.2.. Presence and coordination with other required complementary units or services 3.3.3. Patient care pathways, protocols and clinical guidelines in the field of expertise 3.3.4. External coordination, care management and follow-up of patients 3.3.. Research, training, health technology assessment in the field of expertise 3.3.6. Specific information systems 3.3.7. Do you recommend any additional criteria or option that would effectively address the issue? 3.3.7.1. Space for further comments: Integration of follow-up programs in clinical pathways, evaluation/quality management to achieve treatment and research goals, bridging the gap between children and adults (transitional medicine)